Navigation Links
MiMedx Group, Inc. Board Announces Support for Chairman Parker H. "Pete" Petit
Date:1/11/2012

KENNESAW, Ga., Jan. 11, 2012 /PRNewswire/ -- The Board of Directors of MiMedx Group, Inc. (OTCBB: MDXG), announced today that the Board of Directors fully supports the Company's Chairman and CEO, Parker H. "Pete" Petit, despite the action taken today by the Securities Exchange Commission ("SEC").

The SEC has brought a civil action against Mr. Petit alleging that in 2007, when he was Chairman and CEO of Matria Healthcare, Inc. (formerly listed on NASDAQ), he provided inside information to a friend who subsequently purchased Matria Healthcare stock.  Mr. Petit's attorneys issued a press release regarding this matter earlier today.

Larry W. Papasan, Chairman of the Nominating and Governance Committee of MiMedx's Board, stated, "The independent members of Board of Directors have  reviewed  this situation very closely and are not aware of any direct evidence that would implicate Mr. Petit in any wrongdoing. There is no assertion of any issues on the part of MiMedx, and the independent directors believe that Mr. Petit can continue his able leadership of MiMedx while dealing with this personal, civil matter.  Mr. Petit is a great leader and an outstanding business executive. His lifelong legacy of business accomplishments, civic involvement and philanthropy is exemplary and representative of the highest moral and ethical standards. The Board believes Mr. Petit is deserving of every benefit of the doubt, and, barring unforeseen circumstances or material new developments, looks forward to many more years in which MiMedx and its shareholders will benefit from his leadership and vision."

"The MiMedx Board of Directors and management team are keenly focused on the exciting opportunities ahead of our Company and will continue to dedicate all of our resources to fulfilling our potential," added Papasan.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group, Inc. to Present at the Noble Capital Markets 8th Annual Equity Conference
2. MiMedx Group Receives HCPCS C-Code from Medicare for EpiFix® Reimbursement
3. MiMedx Group Announces Third Quarter 2011 Results
4. MiMedx Groups EpiFix® Receives American Podiatric Medical Association Seal of Approval
5. MiMedx Group Partners With Affirmative Solutions
6. MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
7. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
8. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
9. MiMedx Group, Inc. Announces Release Date for First Quarter Results
10. MiMedx Completes Acquisition of Surgical Biologics
11. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Research and Markets has announced the addition of ... report to their offering. ... Traditional medical devices include devices (e.g., ... implantables, large endoscopes, needle based drug delivery, lab based diagnostics ... to three decades for the treatment and management of various ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... ... Braun Industries will be participating as an exhibitor at EMS Today 2017. ... 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake ... on display. , “JEMS is a leader in EMS news and education. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... in better care, and MEDfx and the Delaware Health Information Network (DHIN) have ... As the nation’s first state-wide health information exchange, DHIN stores and shares real-time ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. – 2:30 ... regulatory burden? Pay dividends in enhanced and predictable product performance? Streamline processes ...
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
Breaking Medicine News(10 mins):